TSE:4568Pharmaceuticals
Is Daiichi Sankyo (TSE:4568) Using MNM Delivery To Quietly Reframe Its Oncology Innovation Story?
In April 2026, Interna Therapeutics announced a research collaboration with Daiichi Sankyo Research Institute Boston to test Interna's MNM technology as a delivery enhancer for targeted therapeutic modalities, initially focused on preclinical evaluation with undisclosed financial terms.
This partnership highlights Daiichi Sankyo's interest in next-generation intracellular delivery platforms that could enhance the performance of nucleic acid and other macromolecule-based therapies across...